
New treatment approach nearly doubles survival in small-cell lung cancer
For people with extensive-stage small-cell lung cancer (ES-SCLC), treatment advances have been limited, and the cancer often returns quickly after initially responding to treatment. But new findings from a large clinical trial may mark a turning point. In the phase 3 DeLLphi-305 trial, people who received tarlatamab (Imdelltra) alongside durvalumab (Imfinzi) after initial chemotherapy and […]










